共 50 条
- [1] A phase I study of RAD1901, an oral selective estrogen receptor degrader, in ER-positive, HER2-negative, postmenopausal advanced breast cancer patients.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Harb, Wael A.Garner, FionaClarkin, MarcieRoberge, Kathleen A.Harris, Alan G.Williams, GregoryHattersley, Gary
- [2] A phase 1 study of RAD1901, a novel, oral selective estrogen receptor degrader, for the treatment of ER-positive advanced breast cancerCANCER RESEARCH, 2017, 77Kaklamani, V. G.Kabos, P.Elledge, R.Harb, W.Purandare, D.O'Neill, A.Garner, F.Bardia, A.
- [3] Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast CancerJOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (12) : 1360 - +Bardia, AdityaKaklamani, VirginiaWilks, SharonWeise, AmyRichards, DonaldHarb, WaelOsborne, CynthiaWesolowski, RobertKaruturi, MeghanConkling, PaulBagley, Rebecca G.Wang, YameiConlan, Maureen G.Kabos, Peter
- [4] A phase 1 study of RAD1901, a novel, orally available, selective estrogen receptor degrader, for the treatment of ER positive advanced breast cancerCANCER RESEARCH, 2016, 76Harb, W.Garner, F.McDermott, J.Zimmerman, T.Williams, G.Hattersley, G.Purandare, D.
- [5] A phase 1 study of RAD1901, an oral selective estrogen receptor degrader, to determine changes in the 18F-FES uptake and tumor responses in ER-positive, HER2-negative, advanced breast cancer patientsCANCER RESEARCH, 2017, 77de Vries, E. G. E.Venema, C. M.Glaudemans, A. W. J. M.Jager, A.Garner, F.O'Neill, A.Patki, A.van Oordt, Menke-van der Houven C. W.
- [6] Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancerCANCER RESEARCH, 2020, 80 (04)Kaklamani, VirginiaBardia, AdityaWilks, SharonWeise, AmyRichards, DonaldHarb, WaelOsborne, CynthiaWesolowski, RobertKaruturi, MeghanConkling, PaulBagley, RebeccaJung, JungAhBihani, TeeruConlan, MaureenKabos, Peter
- [7] Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER plus ) advanced breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Bardia, AdityaKabos, PeterElledge, RichardWang, DannieShen, JinshanGarner, FionaO'Neill, AlisonKaklamani, Virginia G.
- [8] A phase 1 dose escalation study of RAD1901, an oral selective estrogen receptor degrader, in healthy postmenopausal womenCANCER RESEARCH, 2016, 76Hattersley, G.David, F.Harris, A.Clarkin, M.Banks, K.Glaudemans, A. W. J. M.Doorduin, J.Koole, M.de Vries, E. F. J.Williams, G.
- [9] Impact of oral selective estrogen receptor degrader RAD1901 in preclinical models of endocrine sensitive/resistant breast cancerCANCER RESEARCH, 2017, 77Pancholi, SunilNikitorowicz-Buniak, JoannaRibas, RicardoSimigdala, NikianaGarner, FionaBihani, TeeruJohnston, Stephen R.Dowsett, MitchMartin, Lesley-Ann
- [10] RAD1901, a novel tissue-selective estrogen receptor degrader (SERD) demonstrates estrogen receptor engagement in a phase 1 clinical studyCANCER RESEARCH, 2015, 75Hattersley, GaryDavid, FrankHarris, AlanClarkin, MarcieBanks, KateWilliams, GregGlaudemans, AndorDoorduin, JanineKoole, Michelde Vries, ErikLyttle, Rich